EGFR / HER2 / HER3 expression in tumour and gefitinib treatment in Chinese patients with advanced non-small cell lung cancer

Jianming Xu, Emei Gao, Yu Han, Yang Zhang, Suxia Li, Xiaoqing Liu, Zhiqiang Li, Angelo Paradiso

Research output: Contribution to journalArticle

Abstract

Objective: Biological markers performable in routine practice and able to predict the clinical outcome of advanced non-small cell lung cancer (NSCLC) treated with gefitinib are urgently needed. Methods: We analyzed EGFR / HER2 / HER3 primary tumour immunohistochemical expression in a prospective and consecutive series of 90 Chinese patients. Platinum-pretreated patients received a 250 mg oral dose of gefitinib once daily until disease progression; EGFR / HER2 / HER3 tumour status was related with the clinical outcome in terms of response rate (RR), time to disease progression (TTP), and overall survival (OS). Results: A high expression (scores 2-3) of EGFR, HER2 and HER3 was verified in 16.7%, 43.3% and 21.1% of tumors, respectively. EGFR and HER3 status were not significantly related with response, while the HER2 overexpression result was significantly associated with a higher RR (35.9% vs. 15.7%, P = 0.027). The RR in the 13 patients with both HER2 and HER3 expression was also significantly higher than in the other 77 patients (53.8% vs. 22.1%, P = 0.036). EGFR / HER2 / HER3 status was not significantly correlated with TTP or OS. Conclusion: The HER2 immunohistochemical expression can play a role in the clinical management of Chinese patients with advanced NSCLC who are candidates for gefitinib therapy.

Original languageEnglish
Pages (from-to)440-446
Number of pages7
JournalChinese-German Journal of Clinical Oncology
Volume7
Issue number8
DOIs
Publication statusPublished - 2008

Fingerprint

Non-Small Cell Lung Carcinoma
Disease Progression
Neoplasms
Therapeutics
Survival
Platinum
Biomarkers
gefitinib

Keywords

  • EGFR
  • Gefitinib
  • HER2
  • HER3
  • Non-small cell lung cancer (NSCLC)

ASJC Scopus subject areas

  • Oncology

Cite this

EGFR / HER2 / HER3 expression in tumour and gefitinib treatment in Chinese patients with advanced non-small cell lung cancer. / Xu, Jianming; Gao, Emei; Han, Yu; Zhang, Yang; Li, Suxia; Liu, Xiaoqing; Li, Zhiqiang; Paradiso, Angelo.

In: Chinese-German Journal of Clinical Oncology, Vol. 7, No. 8, 2008, p. 440-446.

Research output: Contribution to journalArticle

Xu, Jianming ; Gao, Emei ; Han, Yu ; Zhang, Yang ; Li, Suxia ; Liu, Xiaoqing ; Li, Zhiqiang ; Paradiso, Angelo. / EGFR / HER2 / HER3 expression in tumour and gefitinib treatment in Chinese patients with advanced non-small cell lung cancer. In: Chinese-German Journal of Clinical Oncology. 2008 ; Vol. 7, No. 8. pp. 440-446.
@article{f28b1b03113c4954b263fecf215bad73,
title = "EGFR / HER2 / HER3 expression in tumour and gefitinib treatment in Chinese patients with advanced non-small cell lung cancer",
abstract = "Objective: Biological markers performable in routine practice and able to predict the clinical outcome of advanced non-small cell lung cancer (NSCLC) treated with gefitinib are urgently needed. Methods: We analyzed EGFR / HER2 / HER3 primary tumour immunohistochemical expression in a prospective and consecutive series of 90 Chinese patients. Platinum-pretreated patients received a 250 mg oral dose of gefitinib once daily until disease progression; EGFR / HER2 / HER3 tumour status was related with the clinical outcome in terms of response rate (RR), time to disease progression (TTP), and overall survival (OS). Results: A high expression (scores 2-3) of EGFR, HER2 and HER3 was verified in 16.7{\%}, 43.3{\%} and 21.1{\%} of tumors, respectively. EGFR and HER3 status were not significantly related with response, while the HER2 overexpression result was significantly associated with a higher RR (35.9{\%} vs. 15.7{\%}, P = 0.027). The RR in the 13 patients with both HER2 and HER3 expression was also significantly higher than in the other 77 patients (53.8{\%} vs. 22.1{\%}, P = 0.036). EGFR / HER2 / HER3 status was not significantly correlated with TTP or OS. Conclusion: The HER2 immunohistochemical expression can play a role in the clinical management of Chinese patients with advanced NSCLC who are candidates for gefitinib therapy.",
keywords = "EGFR, Gefitinib, HER2, HER3, Non-small cell lung cancer (NSCLC)",
author = "Jianming Xu and Emei Gao and Yu Han and Yang Zhang and Suxia Li and Xiaoqing Liu and Zhiqiang Li and Angelo Paradiso",
year = "2008",
doi = "10.1007/s10330-008-0070-7",
language = "English",
volume = "7",
pages = "440--446",
journal = "Chinese-German Journal of Clinical Oncology",
issn = "1610-1979",
publisher = "Springer Verlag",
number = "8",

}

TY - JOUR

T1 - EGFR / HER2 / HER3 expression in tumour and gefitinib treatment in Chinese patients with advanced non-small cell lung cancer

AU - Xu, Jianming

AU - Gao, Emei

AU - Han, Yu

AU - Zhang, Yang

AU - Li, Suxia

AU - Liu, Xiaoqing

AU - Li, Zhiqiang

AU - Paradiso, Angelo

PY - 2008

Y1 - 2008

N2 - Objective: Biological markers performable in routine practice and able to predict the clinical outcome of advanced non-small cell lung cancer (NSCLC) treated with gefitinib are urgently needed. Methods: We analyzed EGFR / HER2 / HER3 primary tumour immunohistochemical expression in a prospective and consecutive series of 90 Chinese patients. Platinum-pretreated patients received a 250 mg oral dose of gefitinib once daily until disease progression; EGFR / HER2 / HER3 tumour status was related with the clinical outcome in terms of response rate (RR), time to disease progression (TTP), and overall survival (OS). Results: A high expression (scores 2-3) of EGFR, HER2 and HER3 was verified in 16.7%, 43.3% and 21.1% of tumors, respectively. EGFR and HER3 status were not significantly related with response, while the HER2 overexpression result was significantly associated with a higher RR (35.9% vs. 15.7%, P = 0.027). The RR in the 13 patients with both HER2 and HER3 expression was also significantly higher than in the other 77 patients (53.8% vs. 22.1%, P = 0.036). EGFR / HER2 / HER3 status was not significantly correlated with TTP or OS. Conclusion: The HER2 immunohistochemical expression can play a role in the clinical management of Chinese patients with advanced NSCLC who are candidates for gefitinib therapy.

AB - Objective: Biological markers performable in routine practice and able to predict the clinical outcome of advanced non-small cell lung cancer (NSCLC) treated with gefitinib are urgently needed. Methods: We analyzed EGFR / HER2 / HER3 primary tumour immunohistochemical expression in a prospective and consecutive series of 90 Chinese patients. Platinum-pretreated patients received a 250 mg oral dose of gefitinib once daily until disease progression; EGFR / HER2 / HER3 tumour status was related with the clinical outcome in terms of response rate (RR), time to disease progression (TTP), and overall survival (OS). Results: A high expression (scores 2-3) of EGFR, HER2 and HER3 was verified in 16.7%, 43.3% and 21.1% of tumors, respectively. EGFR and HER3 status were not significantly related with response, while the HER2 overexpression result was significantly associated with a higher RR (35.9% vs. 15.7%, P = 0.027). The RR in the 13 patients with both HER2 and HER3 expression was also significantly higher than in the other 77 patients (53.8% vs. 22.1%, P = 0.036). EGFR / HER2 / HER3 status was not significantly correlated with TTP or OS. Conclusion: The HER2 immunohistochemical expression can play a role in the clinical management of Chinese patients with advanced NSCLC who are candidates for gefitinib therapy.

KW - EGFR

KW - Gefitinib

KW - HER2

KW - HER3

KW - Non-small cell lung cancer (NSCLC)

UR - http://www.scopus.com/inward/record.url?scp=51649119367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51649119367&partnerID=8YFLogxK

U2 - 10.1007/s10330-008-0070-7

DO - 10.1007/s10330-008-0070-7

M3 - Article

AN - SCOPUS:51649119367

VL - 7

SP - 440

EP - 446

JO - Chinese-German Journal of Clinical Oncology

JF - Chinese-German Journal of Clinical Oncology

SN - 1610-1979

IS - 8

ER -